Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (9635)	12/2/2003 4:10:09 PM
From: Icebrg	Respond to of 52153

>>Has there been any talk of a pivotal trial?>> They should have started one already, but no signs so far of this being done. Which is strange considering the strong results seen. Maybe they have "convinced" FDA that considering the circumstances they should be granted a conditional approval with a phase IV requirement. To me that seems to be the sensible thing to do. These people have no alternatives (that I am aware of). No, I don't think this indication will generate enough revenue to turn the company profitable, but it would be nice to see that complement inhibition does actually work. Over time they will find new uses for such a drug. There were for example some marginally positive results from a nephritities trial and we have the RA phase II that is on-going. We are currently seeing ALXN trading above 20, which doesn't make much sense after the CABG studies. Maybe the market is impressed by the fact that they for once appear to have hit a primary endpoint. That doesn't happen too often. Erik